SCHEMBL4065725

SCHEMBL4065725

CCCc1cc(CC(=O)OC)c(C#N)c(OC)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 5/20 0.43
MAPK9 P45984 4/20 0.43
PRKD3 O94806 2/20 0.40
MAP4K4 O95819 2/20 0.40
MAP4K2 Q12851 2/20 0.40
PKN2 Q16513 2/20 0.40
MAP4K5 Q9Y4K4 1/20 0.40
HSD17B10 Q99714 3/20 0.38
PKM P14618 1/20 0.38
RECQL P46063 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
SQOR Q9Y6N5 1/20 0.36
BCAT2 O15382 5/20 0.36
MAPK10 P53779 2/20 0.36
PRKD2 Q9BZL6 1/20 0.36
STK17A Q9UEE5 1/20 0.36
CTSS P25774 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065434 0.82 SQOR (0.43) MAPK8MAPK9HSD17B10RECQLALDH1A1
SCHEMBL4070239 0.82 HSD17B10 (0.46) MAPK8MAPK9HSD17B10PKMRECQL
SCHEMBL4069790 0.79 MAPK8 (0.41) MAPK8MAPK9PRKD3HSD17B10PKM
SCHEMBL4075279 0.78 SQOR (0.62) HSD17B10ALDH1A1HPGDTP53MAPT
SCHEMBL4074987 0.76 TSHR (0.44) MAPK8MAPK9HSD17B10RECQLALDH1A1
SCHEMBL4074633 0.76 RECQL (0.59) MAPK8MAPK9RECQLALDH1A1HPGD
SCHEMBL4069316 0.71 RECQL (0.43) MAPK8MAPK9HSD17B10PKMRECQL
SCHEMBL4064642 0.70 HSD17B10 (0.48) HSD17B10PKMALDH1A1HPGDTP53
SCHEMBL4064564 0.69 ALDH1A1 (0.40) MAPK8MAPK9HSD17B10PKMALDH1A1
SCHEMBL4069859 0.67 SQOR (0.50) HSD17B10ALDH1A1HPGDMAPTSQOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 MAPK8 1290/4885MAPK9 949/4885PRKD3 2427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.